Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.
about
Recognition of live phosphatidylserine-labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancerPleiotropic Effects of IL-2 on Cancer: Its Role in Cervical CancerThe Dichotomy of Tumor Exosomes (TEX) in Cancer Immunity: Is It All in the ConTEXt?The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapyCancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.Tumor-infiltrating dendritic cells in cancer pathogenesisBlocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune responseTumor antigen-specific monoclonal antibodies and induction of T-cell immunityCish actively silences TCR signaling in CD8+ T cells to maintain tumor toleranceAssessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge aheadNanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitorsImmunosuppressive strategies that are mediated by tumor cellsCancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages.Melanoma NOS1 expression promotes dysfunctional IFN signalingTumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes.Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinomaTreg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.Dynamics and potential impact of the immune response to chronic myelogenous leukemiaSimultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancerSelf-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery systemTumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg).Colorectal cancer immunotherapy.IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.Antitumor Effect of KML-B-Treated Dendritic Cells via Induction of Lymphocyte Activation.Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathwayNew aspects of neuroblastoma treatment: ASPHO 2011 symposium reviewOptimal treatment strategy for a tumor model under immune suppression.Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent.T cell-tumor interaction directs the development of immunotherapies in head and neck cancer.Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactionsNormalization of tumor microenvironment by neem leaf glycoprotein potentiates effector T cell functions and therapeutically intervenes in the growth of mouse sarcoma.A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor modelsReal-time monitoring of circulating tumor cell release during tumor manipulation using in vivo photoacoustic and fluorescent flow cytometry.Genetically predisposed, life style and occurrence of metastatic cancerImmune signature of tumor infiltrating immune cells in renal cancer.Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer PatientsGenetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.Cross-talk between tumors can affect responses to therapyLm-LLO-Based Immunotherapies and HPV-Associated DiseaseIncreased P-35, EBI3 Transcripts and Other Treg Markers in Peripheral Blood Mononuclear Cells of Breast Cancer Patients with Different clinical Stages
P2860
Q23918376-9F290037-B45F-40EB-96FE-C5B0B15EC2B3Q26747008-09A19D72-F2C9-4275-8941-B39F0C0B79BBQ26773307-83CC8B51-6E07-4D76-A2B3-A730BBDA5B63Q26783291-34C52BEA-790C-4624-A954-E62ACF6298E0Q26830028-841DF463-CBF3-4DF7-8DA5-E7F30D7DFD01Q26861633-72D84E60-E60C-4D10-AFD2-81698309D400Q26863081-5A50092D-0163-442E-8774-F5251743B9FEQ27009908-E887DEE2-AB51-4C6D-9730-68D5671219B9Q28269352-C07F05AD-15E8-4FC9-9264-868FD690B17BQ28397132-A6AABA5E-FE2C-44F9-AE2F-FCF04ACA5485Q28818166-A5A8E8C8-1B89-4A53-A03B-AC035764F8EBQ29636247-1803EF80-30B7-44BB-B920-F06F467B01CDQ30358706-069D126E-9E12-49BA-A8CE-9B9A2A46ED4EQ30413226-530F191D-FE2E-4DBF-8572-8BB9EE2E3916Q30541774-011A8AFE-3C6B-4024-BDB2-6C6E13FC9847Q33317415-27F33A85-EF65-47C3-B7C4-69681622B4EBQ33330270-F79421EB-0BC1-4A93-ABE4-4276002B168CQ33345245-6E1C343F-5A15-46ED-AEFF-2A9FF3062144Q33482453-8B333C72-39D2-45F0-82B4-6C95FB6A5401Q33633314-8707BEC3-95A0-4C94-B181-417F86653BFDQ33641504-F041D033-C45A-41C8-85BA-8C99DFA59521Q33701465-7536CBA2-A15E-481B-9613-6CA60CD748B2Q33723698-766231FA-668C-4829-8354-4122A62035C4Q33786891-0C14F55F-BC85-4AD3-AF9D-0810DB1A96A3Q33914138-82AF54EE-2C67-48B2-B5ED-F7A6415A1D26Q33922797-FC4A3C2C-5538-417C-833F-40B8287E8867Q34032519-F6381611-75C2-40FA-8BB6-F97A2119E0D3Q34292398-42CA50EA-A244-444E-909F-F9D1AE5D4AF1Q34475726-D5066C45-AD6D-479F-8283-A76A9F816D49Q34477550-0F66C3DA-9A3B-4FB9-86D6-62E745970258Q34778932-C3B3E11B-4F2B-48FC-97C5-D51DB84C6F4EQ34853959-73577F91-9A30-411E-A8FB-46549292A23AQ34892166-46F72D4D-AB35-463F-B437-8D726CA80C07Q35199868-9DF04E22-88A0-4FF3-A05D-FF74D380C797Q35201895-02F596BA-DFAD-445A-92BA-1EF515942D2FQ35629271-BB384143-2E7A-444C-9C3F-3C53FCC751BAQ35783111-336B63A2-A16F-4240-9719-D0A178DE137BQ35799079-C49B46C4-7F76-4CE5-BB06-7A1C241710E2Q35838127-AD28B489-59C9-45C8-9D9F-03E61343319DQ35895255-DED7FAB4-A2BE-4A6B-8252-ECDBC6BB1C51
P2860
Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Immune suppression in cancer: ...... ture therapeutic intervention.
@ast
Immune suppression in cancer: ...... ture therapeutic intervention.
@en
type
label
Immune suppression in cancer: ...... ture therapeutic intervention.
@ast
Immune suppression in cancer: ...... ture therapeutic intervention.
@en
prefLabel
Immune suppression in cancer: ...... ture therapeutic intervention.
@ast
Immune suppression in cancer: ...... ture therapeutic intervention.
@en
P1476
Immune suppression in cancer: ...... ture therapeutic intervention.
@en
P2093
Theresa L Whiteside
P356
10.1016/J.SEMCANCER.2005.07.008
P577
2005-09-08T00:00:00Z